Clinical Trial: Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Study Status: Completed
Recruit Status: Completed
Condition: Steroid Refractory GVHD
Study Type: Interventional
Official Title: Ruxolitinib Add-on in Steroid-refractory Graft-vs-host Disease After Allogeneic Stem Cell Transplantation: a Single Institutional Experience
Brief Summary:
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We sought to evaluate the effect and safety of ruxolitinib (RUX) add-on in the treatment of patients with SR-GVHD.
Read more